- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
Utilizing the Psoriasis Toolbox
Author(s):
In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.
Video Player is loading.
Jerry Bagel, MD, MS, director of the Psoriasis Treatment Center of New Jersey & Eczema Treatment Center of New Jersey in East Windsor, and a member of the National Psoriasis Foundation (NPF) board of directors
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Utility of Head-to-Head Studies in Psoriasis Management
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Mechanism of Action Differences Among IL-17 Inhibitors
Related Content
